{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=5&state=Texas", "query": { "state": "Texas", "city": "San Antonio", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 3151, "total_pages": 316, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=6&state=Texas&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=San+Antonio&page=4&state=Texas&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T12:32:00.112Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colon Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Esophageal Carcinoma", "Exocrine Pancreas Carcinoma", "Gastric Carcinoma", "Glioma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Kidney Carcinoma", "Liver Carcinoma", "Lung Carcinoma", "Lymphoma", "Malignant Uterine Corpus Neoplasm", "Malignant Uterine Neoplasm", "Melanoma", "Multiple Myeloma", "Ovarian Carcinoma", "Prostate Carcinoma", "Rectal Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Colon Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Glioma", "Recurrent Head and Neck Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Melanoma", "Recurrent Multiple Myeloma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Skin Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma", "Skin Carcinoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Defactinib Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Fexagratinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib", "type": "DRUG" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "PI3K-beta Inhibitor GSK2636771", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6452, "start_date": "2015-08-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 1405, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465060" }, { "nct_id": "NCT06628908", "title": "Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Peripheral Neuropathic Pain" ], "interventions": [ { "name": "Suzetrigine", "type": "DRUG" }, { "name": "Placebo (matched to SUZ)", "type": "DRUG" }, { "name": "Pregabalin", "type": "DRUG" }, { "name": "Placebo (matched to Pregabalin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1100, "start_date": "2024-10-01", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 76, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06628908" }, { "nct_id": "NCT00027625", "title": "Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-01-28", "completion_date": "2005-11-01", "has_results": false, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027625" }, { "nct_id": "NCT05819359", "title": "Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "BIA 28-6156 10 mg", "type": "DRUG" }, { "name": "BIA 28-6156 60 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bial R&D Investments, S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "35 Years to 80 Years" }, "enrollment_count": 237, "start_date": "2023-03-31", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 43, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05819359" }, { "nct_id": "NCT01650298", "title": "Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Drug (Direct thrombin or Factor Xa inhibitor)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2013-01", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2020-08-13", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 10, "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01650298" }, { "nct_id": "NCT00047320", "title": "Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor", "Central Nervous System Tumors", "Childhood Germ Cell Tumor" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "3 Years to 24 Years" }, "enrollment_count": 104, "start_date": "2004-01", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 90, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047320" }, { "nct_id": "NCT06136559", "title": "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2023-12-13", "completion_date": "2032-09-07", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 49, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Prescott", "state": "Arizona" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136559" }, { "nct_id": "NCT02468583", "title": "Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-traumatic Osteoarthritis of the Knee" ], "interventions": [ { "name": "FX006 32 mg", "type": "DRUG" }, { "name": "TCA IR 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pacira Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "20 Years to 50 Years" }, "enrollment_count": 6, "start_date": "2015-02", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02468583" }, { "nct_id": "NCT06296459", "title": "Radiographic Changes in the Maxillary Sinus Following Closed Sinus Augmentation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dental Implant" ], "interventions": [ { "name": "3D R100 scanner", "type": "OTHER" }, { "name": "Conventional Radiograph", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 25, "start_date": "2022-09-21", "completion_date": "2024-12-19", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06296459" }, { "nct_id": "NCT00003127", "title": "S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "FEMALE", "summary": "16 Years and older · Female only" }, "enrollment_count": 57, "start_date": "1998-02", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2012-06-14", "last_synced_at": "2026-11-02T12:32:00.112Z", "location_count": 94, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003127" } ] }